- Home
- OPHC vs ARMP Comparison
OPHC vs ARMP Comparison
Compare OPHC & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- ARMP
- Stock Information
- Founded
- OPHC 2000
- ARMP N/A
- Country
- OPHC United States
- ARMP United States
- Employees
- OPHC N/A
- ARMP N/A
- Industry
- OPHC Major Banks
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPHC Finance
- ARMP Health Care
- Exchange
- OPHC Nasdaq
- ARMP Nasdaq
- Market Cap
- OPHC 51.8M
- ARMP 52.1M
- IPO Year
- OPHC N/A
- ARMP N/A
- Fundamental
- Price
- OPHC $4.52
- ARMP $1.94
- Analyst Decision
- OPHC
- ARMP Strong Buy
- Analyst Count
- OPHC 0
- ARMP 1
- Target Price
- OPHC N/A
- ARMP $9.00
- AVG Volume (30 Days)
- OPHC 8.2K
- ARMP 20.6K
- Earning Date
- OPHC 08-05-2025
- ARMP 08-12-2025
- Dividend Yield
- OPHC N/A
- ARMP N/A
- EPS Growth
- OPHC 30.24
- ARMP N/A
- EPS
- OPHC 1.33
- ARMP N/A
- Revenue
- OPHC $39,980,000.00
- ARMP $4,699,000.00
- Revenue This Year
- OPHC N/A
- ARMP $8.43
- Revenue Next Year
- OPHC N/A
- ARMP N/A
- P/E Ratio
- OPHC $3.37
- ARMP N/A
- Revenue Growth
- OPHC 53.28
- ARMP 14.24
- 52 Week Low
- OPHC $3.53
- ARMP $0.90
- 52 Week High
- OPHC $5.90
- ARMP $3.42
- Technical
- Relative Strength Index (RSI)
- OPHC 56.95
- ARMP 52.89
- Support Level
- OPHC $4.42
- ARMP $1.85
- Resistance Level
- OPHC $4.62
- ARMP $2.00
- Average True Range (ATR)
- OPHC 0.06
- ARMP 0.15
- MACD
- OPHC 0.01
- ARMP -0.01
- Stochastic Oscillator
- OPHC 61.54
- ARMP 52.63
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, money market deposit accounts, debit cards, and automated teller machines.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.